N-acetylcysteine for repeated self-injury in Cornelia de Lange syndrome
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This Phase 2 trial tests whether a supplement-like medicine called N-acetylcysteine (NAC) can reduce repetitive behaviors and self-injurious behaviors in people with Cornelia de Lange syndrome (CdLS). It also checks safety over about 18 weeks at Johns Hopkins Hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 13 to 35 years old
- A doctor must confirm you have Cornelia de Lange syndrome (CdLS)
- Your screening scores suggest you have enough repetitive behavior and/or self-injury (measured on behavior questionnaires)
- You (or your caregiver) can attend 4 visits over 18 weeks at Johns Hopkins Hospital
- You should not have urgent safety problems needing hospitalization for major mood or mental health episodes
- You should not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a structured behavior assessment and treatment program for children with Cornelia de Lange syndrome who have challenging behaviors. It may help reduce self-injury, aggression, and disruptive behavior through a plan families can carry out.
This trial tests whether lithium can help people with Cornelia de Lange syndrome (CdLS) who have a confirmed NIPBL gene mutation. It might improve their daily life and overall well-being.
This study looks at how to reduce serious problem behaviors (including self-injury) in children who have it many times per day even after previous treatment. It may help if your child’s behavior is driven by social attention or other positive effects and they can stay on the same supports, school plan, and medicines during the study.
This study tests whether N-acetyl cysteine (a supplement-like medicine) changes body and brain function in people with multiple sclerosis. It may help researchers understand how it affects brain chemistry and activity using special brain imaging.
This Phase 2 study tests whether a single dose of N-acetylcysteine can improve “restricted and repetitive behaviors” in children with autism. It’s meant for kids who are stable and still in early puberty stages.
This trial studies whether N-acetylcysteine, a medicine taken by mouth, can improve autism-related restricted and repetitive behaviors in children. It looks at children who are showing at least moderate severity in these behaviors and may involve brain testing for safety reasons.
Hear when a new Cornelia de Lange Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.